Drug Profile
Research programme: curcumin formulations - Signpath Pharma
Alternative Names: Diferuloylmethane formulations - Signpath Pharma; Extended-release PLGA-curcumin; Nano curcumin; Nanocurc; PLGA-liposomal-curcumin; Polylactic coglycolic acid liposomal curcumin; Polymeric nanocurcuminLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Johns Hopkins Medical Institutions; University of North Texas Health Science Center
- Developer Signpath Pharma
- Class Catechols
- Mechanism of Action Inflammation mediator modulators; NF-kappa B inhibitors; Proto oncogene protein c-akt inhibitors; Toll-like receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Diabetic complications; Neurodegenerative disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetic-complications(Prevention) in USA (SC)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA (Parenteral)